Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial

Biotech Investing

Cidara Therapeutics (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported positive topline results from the global, randomized Phase 2 STRIVE clinical trial of its lead antifungal candidate rezafungin acetate. As quoted in the press release: “We extend sincere thanks to our STRIVE participants, investigators and their site staff for their dedication and …

As quoted in the press release:

“We extend sincere thanks to our STRIVE participants, investigators and their site staff for their dedication and execution of this trial. This is the first time that any antifungal has shown the potential to be a safe and effective once-weekly treatment option for patients with difficult-to-treat and deadly invasive Candida infections, which may enable patients to leave the hospital earlier, saving money and improving care,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “It is especially encouraging to note the consistent trends in relative outcomes improvement among patients on the rezafungin 400/200 regimen as compared to those on the comparator caspofungin. With these data in hand, we can confidently select the dosing regimens for our two upcoming Phase 3 pivotal trials of rezafungin in treatment and prophylaxis.”

Click here to read the full press release.

patients therapeutics treatment option trials Biotech Investing